{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:12:56Z","timestamp":1792098776378,"version":"4.4.0"},"reference-count":197,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T00:00:00Z","timestamp":1682208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["19H03678"],"award-info":[{"award-number":["19H03678"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Regulation and action of the mineralocorticoid receptor (MR) have been the focus of intensive research over the past 80 years. Genetic and physiological\/biochemical analysis revealed how MR and the steroid hormone aldosterone integrate the responses of distinct tubular cells in the face of environmental perturbations and how their dysregulation compromises fluid homeostasis. In addition to these roles, the accumulation of data also provided unequivocal evidence that MR is involved in the pathophysiology of kidney diseases. Experimental studies delineated the diverse pathological consequences of MR overactivity and uncovered the multiple mechanisms that result in enhanced MR signaling. In parallel, clinical studies consistently demonstrated that MR blockade reduces albuminuria in patients with chronic kidney disease. Moreover, recent large-scale clinical studies using finerenone have provided evidence that the non-steroidal MR antagonist can retard the kidney disease progression in diabetic patients. In this article, we review experimental data demonstrating the critical importance of MR in mediating renal injury as well as clinical studies providing evidence on the renoprotective effects of MR blockade. We also discuss areas of future investigation, which include the benefit of non-steroidal MR antagonists in non-diabetic kidney disease patients, the identification of surrogate markers for MR signaling in the kidney, and the search for key downstream mediators whereby MR blockade confers renoprotection. Insights into these questions would help maximize the benefit of MR blockade in subjects with kidney diseases.<\/jats:p>","DOI":"10.3390\/ijms24097719","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T04:01:23Z","timestamp":1682308883000},"page":"7719","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0748-2876","authenticated-orcid":false,"given":"Wataru","family":"Fujii","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Graduate School of Medicine, Teikyo University, Tokyo 173-8605, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6868-0626","authenticated-orcid":false,"given":"Shigeru","family":"Shibata","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Graduate School of Medicine, Teikyo University, Tokyo 173-8605, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/139925a0","article-title":"Partial Synthesis of a Crystallized Compound with the Biological Activity of the Adrenal-cortical Hormone","volume":"139","author":"Steiger","year":"1937","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.bi.15.070146.002023","article-title":"The chemistry of the hormones","volume":"15","author":"Selye","year":"1946","journal-title":"Annu. Rev. Biochem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1084\/jem.68.2.161","article-title":"The effect of corticosterone and related compounds on the renal excretion of electrolytes","volume":"68","author":"Thorn","year":"1938","journal-title":"J. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1172\/JCI101060","article-title":"Treatment of addison\u2019s disease with desoxy-corticosterone acetate, a synthetic adrenal cortical hormone (preliminary report)","volume":"18","author":"Thorn","year":"1939","journal-title":"J. Clin. Investig."},{"key":"ref_5","first-page":"226","article-title":"The treatment of addison\u2019s disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate)","volume":"41","author":"Cleghorn","year":"1939","journal-title":"Can. Med. Assoc. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.1.4296.557","article-title":"Desoxycorticosterone in Addison\u2019s Disease","volume":"1","author":"Dunlop","year":"1943","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1530\/JOE-11-0178","article-title":"The mislabelling of deoxycorticosterone: Making sense of corticosteroid structure and function","volume":"211","author":"Vinson","year":"2011","journal-title":"J. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1126\/science.90.2343.496","article-title":"Toxic Effects of Desoxycorticosterone Esters in Dogs","volume":"90","author":"Kuhlmann","year":"1939","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.1944.02850330028007","article-title":"Effect of desoxycorticosterone acetate on the blood pressure of man","volume":"125","author":"Perera","year":"1944","journal-title":"JAMA"},{"key":"ref_10","first-page":"88","article-title":"Malignant Hypertension Produced by Treatment with Desoxycorticosterone Acetate and Sodium Chloride","volume":"49","author":"Selye","year":"1943","journal-title":"Can. Med. Assoc. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/169795a0","article-title":"Isolation of a Highly Active Mineralocorticoid from Beef Adrenal Extract","volume":"169","author":"Grundy","year":"1952","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02155834","article-title":"Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism","volume":"9","author":"Simpson","year":"1953","journal-title":"Experientia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF02158515","article-title":"Constitution of aldosterone, a new mineralocorticoid","volume":"10","author":"Simpson","year":"1954","journal-title":"Experientia"},{"key":"ref_14","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J. Lab. Clin. Med."},{"key":"ref_15","first-page":"215","article-title":"Primary aldosteronism: A new clinical entity","volume":"68","author":"Conn","year":"1955","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/imj.1970.19.4.287","article-title":"Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction","volume":"19","author":"Gordon","year":"1970","journal-title":"Australas. Ann. Med."},{"key":"ref_17","first-page":"1109","article-title":"Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone","volume":"95","author":"Sutherland","year":"1966","journal-title":"Can. Med. Assoc. J."},{"key":"ref_18","first-page":"199","article-title":"A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion","volume":"76","author":"Gw","year":"1963","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","article-title":"Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt","volume":"126","author":"Kagawa","year":"1957","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.126.3281.1016","article-title":"Sodium Diuresis Induced by Steroidal Antagonists of Aldosterone","volume":"126","author":"Liddle","year":"1957","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1210\/jcem-19-12-1683","article-title":"The role of potassium in the natriuretic response to a steroidal lactone (sc-9420)","volume":"19","author":"Taylor","year":"1959","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"(1960). The Spirolactones. Br. Med. J., 2, 364\u2013365.","DOI":"10.1136\/bmj.2.5195.364"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of Human Mineralocorticoid Receptor Complementary DNA: Structural and Functional Kinship with the Glucocorticoid Receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/361467a0","article-title":"Epithelial sodium channel related to proteins involved in neurodegeneration","volume":"361","author":"Canessa","year":"1993","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/367463a0","article-title":"Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits","volume":"367","author":"Canessa","year":"1994","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0092-8674(01)00241-0","article-title":"Molecular Mechanisms of Human Hypertension","volume":"104","author":"Lifton","year":"2001","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"LIfton","year":"1992","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating Mineralocorticoid Receptor Mutation in Hypertension Exacerbated by Pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0092-8674(94)90250-X","article-title":"Liddle\u2019s syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel","volume":"79","author":"Shimkets","year":"1994","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ng0396-248","article-title":"Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1","volume":"12","author":"Chang","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ng0696-248","article-title":"A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families","volume":"13","author":"Strautnieks","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0006-291X(92)91827-D","article-title":"Congenitally defective aldosterone biosynthesis in humans: The involvement of point mutations of the P-450C18 gene (CYP11B2) in CMO II deficient patients","volume":"182","author":"Mitsuuchi","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1073\/pnas.89.11.4996","article-title":"Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency","volume":"89","author":"Pascoe","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/966","article-title":"Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I","volume":"19","author":"Geller","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e06315","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"eLife"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1504869","article-title":"Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations","volume":"373","author":"Teo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41588-021-00906-y","article-title":"Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause","volume":"53","author":"Zhou","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cmet.2013.10.005","article-title":"Mineralocorticoid Receptor Phosphorylation Regulates Ligand Binding and Renal Response to Volume Depletion and Hyperkalemia","volume":"18","author":"Shibata","year":"2013","journal-title":"Cell Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/JOE-16-0669","article-title":"30 years of the mineralocorticoid receptor: Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron","volume":"234","author":"Shibata","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1681\/ASN.2017030243","article-title":"Aldosterone Is Essential for Angiotensin II-Induced Upregulation of Pendrin","volume":"29","author":"Hirohama","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.celrep.2018.06.072","article-title":"ULK1 Phosphorylates and Regulates Mineralocorticoid Receptor","volume":"24","author":"Shibata","year":"2018","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/CS20180194","article-title":"Electrolyte transport in the renal collecting duct and its regulation by the renin\u2013angiotensin\u2013aldosterone system","volume":"133","author":"Yamazaki","year":"2019","journal-title":"Clin. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1681\/ASN.2019080804","article-title":"Two Mineralocorticoid Receptor\u2013Mediated Mechanisms of Pendrin Activation in Distal Nephrons","volume":"31","author":"Ayuzawa","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMra2030212","article-title":"Insights into Salt Handling and Blood Pressure","volume":"385","author":"Ellison","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Yamazaki, O., Hirohama, D., Ishizawa, K., and Shibata, S. (2020). Role of the Ubiquitin Proteasome System in the Regulation of Blood Pressure: A Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155358"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15556","DOI":"10.1073\/pnas.1418342111","article-title":"Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation","volume":"111","author":"Shibata","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","first-page":"E879","article-title":"Phosphorylation by PKC and PKA regulate the kinase activity and downstream signaling of WNK4","volume":"114","author":"Arroyo","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1073\/pnas.1817281116","article-title":"Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling","volume":"116","author":"Ishizawa","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1113\/JP276844","article-title":"K+ and the renin\u2013angiotensin\u2013aldosterone system: New insights into their role in blood pressure control and hypertension treatment","volume":"597","author":"Poulsen","year":"2019","journal-title":"J. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","article-title":"Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone","volume":"79","author":"Maeoka","year":"2022","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00424-022-02732-5","article-title":"Regulation of distal tubule sodium transport: Mechanisms and roles in homeostasis and pathophysiology","volume":"474","author":"Pearce","year":"2022","journal-title":"Pfl\u00fcgers Arch."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/HYPERTENSIONAHA.121.16492","article-title":"Regulation of Blood Pressure and Salt Balance by Pendrin-Positive Intercalated Cells: Donald Seldin Lecture 2020","volume":"79","author":"Wall","year":"2022","journal-title":"Hypertension"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/endo-38-5-315","article-title":"Influence of adrenal cortical steroids upon the blood pressure and the rate of progression of experimental nephritis in rats","volume":"38","author":"Knowlton","year":"1946","journal-title":"Endocrinology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0033-0620(74)90037-1","article-title":"Renin and aldosterone and the pathogenesis of hypertensive vascular damage","volume":"17","author":"Gavras","year":"1974","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000182122","article-title":"Heymann nephritis-DOCA-NaCl hypertension in the rat. Role of nephritis, DOCA, NaCl, and vascular lesions in the development of hypertension","volume":"28","author":"Tikkanen","year":"1981","journal-title":"Nephron"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1172\/JCI115949","article-title":"Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass","volume":"90","author":"Lafayette","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_68","first-page":"F781","article-title":"Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron","volume":"264","author":"Schnermann","year":"1993","journal-title":"Am. J. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/jmedgenet-2012-101442","article-title":"ARHGDIA: A novel gene implicated in nephrotic syndrome","volume":"50","author":"Gupta","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1172\/JCI69134","article-title":"ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling","volume":"123","author":"Gee","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db\/db Mice","volume":"78","author":"Hirohama","year":"2021","journal-title":"Hypertension"},{"key":"ref_75","first-page":"606","article-title":"The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis","volume":"4","author":"Zitt","year":"2011","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.2012111094","article-title":"Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease","volume":"25","author":"Huang","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/01.ju.0000140445.82949.54","article-title":"Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction","volume":"172","author":"Trachtman","year":"2004","journal-title":"J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000473702","article-title":"The Inhibitory Effect of Eplerenone on Cell Proliferation in the Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction","volume":"136","author":"Wang","year":"2017","journal-title":"Nephron"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1681\/ASN.2016040477","article-title":"Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1","volume":"28","author":"Cat","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury","volume":"83","author":"Reyna","year":"2013","journal-title":"Kidney Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1074\/jbc.M607741200","article-title":"Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9","volume":"282","author":"Yokota","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/en.2009-1476","article-title":"Activation of Mineralocorticoid Receptors by Exogenous Glucocorticoids and the Development of Cardiovascular Inflammatory Responses in Adrenalectomized Rats","volume":"151","author":"Young","year":"2010","journal-title":"Endocrinology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: Role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1536\/ihj.16-649","article-title":"High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C \u03b2 Signaling","volume":"58","author":"Hayashi","year":"2017","journal-title":"Int. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mce.2018.01.007","article-title":"Epidermal growth factor receptor\/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization","volume":"473","author":"Mitsuishi","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"19619","DOI":"10.1073\/pnas.1908706116","article-title":"The single-cell transcriptomic landscape of early human diabetic nephropathy","volume":"116","author":"Wilson","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014Mechanistic and therapeutic effects","volume":"18","author":"Bakris","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone Promotes Vascular Remodeling by Direct Effects on Smooth Muscle Cell Mineralocorticoid Receptors","volume":"34","author":"Pruthi","year":"2014","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/ATVBAHA.115.307031","article-title":"Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Neointimal Hyperplasia and Suppresses Macrophage Inflammation through SGK1-AP1\/NF-\u03baB Pathways","volume":"36","author":"Sun","year":"2016","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000480652","article-title":"The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature","volume":"46","author":"Belden","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1074\/jbc.M116.739243","article-title":"Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Atherosclerosis by Affecting Foam Cell Formation and Efferocytosis","volume":"292","author":"Shen","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/ATVBAHA.119.312954","article-title":"Endothelial Mineralocorticoid Receptors Contribute to Vascular Inflammation in Atherosclerosis in a Sex-Specific Manner","volume":"39","author":"Moss","year":"2019","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00230355","article-title":"Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat","volume":"425","author":"Kretzler","year":"1994","journal-title":"Virchows Arch."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1159\/000228080","article-title":"Aldosterone Induces Apoptosis in Rat Podocytes: Role of PI3-K\/Akt and p38MAPK Signaling Pathways","volume":"113","author":"Chen","year":"2009","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e00355","DOI":"10.1042\/BSR20160086","article-title":"Spironolactone promotes autophagy via inhibiting PI3K\/AKT\/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress","volume":"36","author":"Li","year":"2016","journal-title":"Biosci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"F556","DOI":"10.1152\/ajprenal.00332.2016","article-title":"NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury","volume":"312","author":"Bai","year":"2017","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/labinvest.2015.118","article-title":"The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone\/mineralocorticoid receptor-induced podocyte injury","volume":"95","author":"Yuan","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/ndt\/gfp371","article-title":"Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies\u2014The effect on podocytes","volume":"24","author":"Nemeth","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000334961","article-title":"Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis","volume":"2","author":"Takagi","year":"2012","journal-title":"Nephron Extra"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte Injury Underlies the Glomerulopathy of Dahl Salt-Hypertensive Rats and Is Reversed by Aldosterone Blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajh.2011.245","article-title":"Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension","volume":"25","author":"Shibata","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1172\/JCI46458","article-title":"Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis","volume":"121","author":"Akilesh","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1128\/MCB.00730-13","article-title":"Rac1 Activation in Podocytes Induces Rapid Foot Process Effacement and Proteinuria","volume":"33","author":"Yu","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.kint.2017.03.010","article-title":"Rac1 activation in podocytes induces the spectrum of nephrotic syndrome","volume":"92","author":"Robins","year":"2017","journal-title":"Kidney Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1681\/ASN.2016091021","article-title":"Kindlin-2 Association with Rho GDP-Dissociation Inhibitor \u03b1 Suppresses Rac1 Activation and Podocyte Injury","volume":"28","author":"Sun","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1681\/ASN.2017121338","article-title":"The Human FSGS-Causing ANLN R431C Mutation Induces Dysregulated PI3K\/AKT\/mTOR\/Rac1 Signaling in Podocytes","volume":"29","author":"Hall","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.aal4178","article-title":"A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models","volume":"358","author":"Zhou","year":"2017","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.ekir.2021.07.006","article-title":"Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients with Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design","volume":"6","author":"Walsh","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor\u2013dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.mce.2011.07.018","article-title":"Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome","volume":"350","author":"Shibata","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/hr.2016.137","article-title":"Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension","volume":"40","author":"Shibata","year":"2017","journal-title":"Hypertens. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.06054","article-title":"Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload\u2013Induced Cardiac Injury","volume":"67","author":"Ayuzawa","year":"2016","journal-title":"Hypertension"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1074\/jbc.M116.764449","article-title":"Rac1 GTPase regulates 11\u03b2 hydroxysteroid dehydrogenase type 2 and fibrotic remodeling","volume":"292","author":"Lavall","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"C1512","DOI":"10.1152\/ajpcell.00272.2021","article-title":"Interleukin 6 mediated activation of the mineralocorticoid receptor in the aldosterone-sensitive distal nephron","volume":"323","author":"Wynne","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress","volume":"9","author":"Somoza","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.kint.2018.08.024","article-title":"Aldosterone induces albuminuria via matrix metalloproteinase\u2013dependent damage of the endothelial glycocalyx","volume":"95","author":"Butler","year":"2019","journal-title":"Kidney Int."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1681\/ASN.2005020129","article-title":"Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A","volume":"16","author":"Terada","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2006.07.057","article-title":"Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells","volume":"348","author":"Lai","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_126","first-page":"180","article-title":"Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells","volume":"40","author":"Yuan","year":"2007","journal-title":"J. Biochem. Mol. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/ndt\/gfm410","article-title":"Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor","volume":"22","author":"Gauer","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"F1287","DOI":"10.1152\/ajprenal.00017.2008","article-title":"Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells","volume":"294","author":"Huang","year":"2008","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.ki.5000201","article-title":"Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury","volume":"69","author":"Ma","year":"2006","journal-title":"Kidney Int."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sogawa, Y., Nagasu, H., Itano, S., Kidokoro, K., Taniguchi, S., Takahashi, M., Kadoya, H., Satoh, M., Sasaki, T., and Kashihara, N. (2018). The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203823"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Estrela","year":"2018","journal-title":"Kidney Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1159\/000339500","article-title":"Aldosterone Induces Kidney Fibroblast Proliferation via Activation of Growth Factor Receptors and PI3K\/MAPK Signalling","volume":"120","author":"Huang","year":"2012","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","article-title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis","volume":"12","author":"Luther","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2008020232","article-title":"Aldosterone activates NF-kappaB in the collecting duct","volume":"20","author":"Leroy","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Fernandez, B., Rubio-Navarro, A., Cortegano, I., Ballesteros, S., Alia, M., Cannata-Ortiz, P., Olivares-Alvaro, E., Egido, J., De Andr\u00e9s, B., and Gaspar, M.L. (2016). Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0145946"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.121.17712","article-title":"Neutrophil Gelatinase-Associated Lipocalin from Macrophages Plays a Critical Role in Renal Fibrosis Via the CCL5 (Chemokine Ligand 5)-Th2 Cells-IL4 (Interleukin 4) Pathway","volume":"79","author":"Bonnard","year":"2022","journal-title":"Hypertension"},{"key":"ref_138","first-page":"401","article-title":"Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism","volume":"45","author":"Beevers","year":"1976","journal-title":"QJM Int. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: Results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-19-0047","article-title":"Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism","volume":"181","author":"Kawashima","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1378\/chest.100.4.1160","article-title":"Localization of Occult Bronchogenic Carcinoma by Bronchography","volume":"100","author":"Brown","year":"1991","journal-title":"Chest"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative Glomerular Hyperfiltration in Primary Aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/jc.2013-2180","article-title":"Predictors of Decreasing Glomerular Filtration Rate and Prevalence of Chronic Kidney Disease after Treatment of Primary Aldosteronism: Renal Outcome of 213 Cases","volume":"99","author":"Iwakura","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cen.12497","article-title":"Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism","volume":"81","author":"Naruse","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.121.17436","article-title":"Renal Injuries in Primary Aldosteronism: Quantitative Histopathological Analysis of 19 Patients with Primary Adosteronism","volume":"78","author":"Ogata","year":"2021","journal-title":"Hypertension"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal Disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"425","DOI":"10.34067\/KID.0006782020","article-title":"Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial","volume":"2","author":"Agarwal","year":"2021","journal-title":"Kidney360"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: A double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41440-018-0201-7","article-title":"Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non-diabetic hypertension: A sub-analysis of evaluate study","volume":"42","author":"Nishimoto","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The Kidney Protective Effects of the Sodium\u2013Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients with CKD Treated with Mineralocorticoid Receptor Antagonists","volume":"7","author":"Provenzano","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: A phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J. Hum. Hypertens."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","article-title":"Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: A single-arm, open-label study","volume":"42","author":"Itoh","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","article-title":"Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension","volume":"42","author":"Rakugi","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","article-title":"Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: A multicenter, single-arm, open-label phase III study","volume":"25","author":"Ito","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41440-022-01008-w","article-title":"The renoprotective effect of esaxerenone independent of blood pressure lowering: A post hoc mediation analysis of the ESAX-DN trial","volume":"46","author":"Okuda","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","article-title":"Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: Findings from esaxerenone","volume":"44","author":"Rakugi","year":"2020","journal-title":"Hypertens. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jdi.13778","article-title":"Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium\u2013glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies","volume":"13","author":"Shikata","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes by Sodium\u2013Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"McGill, J.B., Agarwal, R., Anker, S.D., Bakris, G.L., Filippatos, G., Pitt, B., Ruilope, L.M., Birkenfeld, A.L., Caramori, M.L., and Brinker, M. (2023). Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes. Metab.","DOI":"10.2337\/db22-16-LB"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood Pressure and Cardiorenal Outcomes with Finerenone in Chronic Kidney Disease in Type 2 Diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2022","journal-title":"J. Hypertens."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"110210","DOI":"10.1016\/j.diabres.2022.110210","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis","volume":"195","author":"Chen","year":"2022","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/dom.14976","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients","volume":"25","author":"Morita","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/HYPERTENSIONAHA.121.18360","article-title":"Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients with Chronic Kidney Disease","volume":"79","author":"Oka","year":"2022","journal-title":"Hypertension"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 102, S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_182","unstructured":"(2023, February 27). A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants with Non-diabetic Chronic Kidney Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05047263."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.16966\/2470-1009.137","article-title":"Pharmacological Profile of KBP-5074, a Novel NonSteroidal Mineralocorticoid Receptor Antagonist for the Treatment of Cardiorenal Diseases","volume":"3","author":"Cp","year":"2017","journal-title":"J. Drug Res. Dev."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: Results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1745-6215-15-160","article-title":"Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial\u2013a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: Study protocol for a randomized controlled trial","volume":"15","author":"Hill","year":"2014","journal-title":"Trials"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s13063-018-2956-1","article-title":"EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: Study protocol for a randomized controlled trial","volume":"19","author":"Girerd","year":"2018","journal-title":"Trials"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1042\/CS20220212","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease","volume":"136","author":"Gerarduzzi","year":"2022","journal-title":"Clin. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41440-021-00756-5","article-title":"Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.kint.2018.09.024","article-title":"Sodium and water handling during hemodialysis: New pathophysiologic insights and management approaches for improving outcomes in end-stage kidney disease","volume":"95","author":"Canaud","year":"2019","journal-title":"Kidney Int."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"105416","DOI":"10.1016\/j.isci.2022.105416","article-title":"Urinary extracellular vesicles signature for diagnosis of kidney disease","volume":"25","author":"Takizawa","year":"2022","journal-title":"iScience"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41440-023-01169-2","article-title":"Significance of podocyte DNA damage and glomerular DNA methylation in CKD patients with proteinuria","volume":"46","author":"Yoshimoto","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41440-021-00710-5","article-title":"Characterization of pendrin in urinary extracellular vesicles in a rat model of aldosterone excess and in human primary aldosteronism","volume":"44","author":"Tsurutani","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): A prospective observational study and embedded randomised placebo-controlled trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e001501","DOI":"10.1136\/bmjdrc-2020-001501","article-title":"Methylation pattern of urinary DNA as a marker of kidney function decline in diabetes","volume":"8","author":"Marumo","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/7719\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:21:37Z","timestamp":1760124097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/9\/7719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,23]]},"references-count":197,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24097719"],"URL":"https:\/\/doi.org\/10.3390\/ijms24097719","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,23]]}}}